Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DCR-STAT3 · 1 trial · 2 indications
safety and tolerability
measured according to CTCAE 5.0 criteria
| Arm | Type | Description |
|---|---|---|
| DCR-STAT3 | EXPERIMENTAL | DCR-STAT3 |
| Name | Type | Description |
|---|---|---|
| DCR-STAT3 | DRUG | DCR-STAT3 is a sterile, preservative-free solution in WFI that will be diluted in a suitable admixture diluent (0.9% normal saline) prior to IV infusion. |
Inclusion Criteria: * Age * ≥ 18 years of age inclusive, at the time of signing the informed consent. Type of Participant and Disease Characteristics \- Documented locally advanced or metastatic solid tumor malignancy or non-Hodgkin's lymphoma that is refractory to standard therapy known to provi...
DCR-STAT3 is an investigational small molecule being developed for the treatment of solid tumors in adults, including refractory tumors. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
DCR-STAT3 is a small molecule that targets STAT3, a protein involved in tumor growth and survival. By inhibiting STAT3, the drug aims to interfere with cancer cell signaling pathways, potentially slowing or stopping tumor progression.
DCR-STAT3 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with solid tumors.
DCR-STAT3 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The Phase 1 trial has been completed, and the drug remains under evaluation for safety and dosing.
DCR-STAT3 has one completed Phase 1 clinical trial, identified as NCT06098651, titled 'A Study of DCR-STAT3 in Adults With Solid Tumors.' The trial enrolled 26 participants in the United States and included adults aged 18 years and older with solid tumors, including refractory tumors.
DCR-STAT3 is the primary name for this investigational drug. No alternative names have been reported in the available clinical trial information. It is a distinct small molecule being studied for its potential role in treating solid tumors.